Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuphoria Therapeutics (NEUP) Intangibles (2020 - 2025)

Neuphoria Therapeutics (NEUP) has disclosed Intangibles for 5 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • On a quarterly basis, Intangibles fell 12.9% to $4.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $4.5 million, a 12.9% decrease, with the full-year FY2025 number at $4.8 million, changed N/A from a year prior.
  • Intangibles was $4.5 million for Q4 2025 at Neuphoria Therapeutics, down from $4.6 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $7.0 million in Q2 2022 to a low of $4.5 million in Q4 2025.
  • A 4-year average of $5.3 million and a median of $5.1 million in 2024 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 12.5% in 2025; the steepest drop was 12.9% in 2025.
  • Neuphoria Therapeutics' Intangibles stood at $7.0 million in 2022, then dropped by 12.72% to $6.2 million in 2023, then decreased by 16.49% to $5.1 million in 2024, then decreased by 12.9% to $4.5 million in 2025.
  • Per Business Quant, the three most recent readings for NEUP's Intangibles are $4.5 million (Q4 2025), $4.6 million (Q3 2025), and $4.8 million (Q2 2025).